Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
Merck & Co forecasts lower 2026 sales and profits due to post-patent challenges for key drugs like Januvia, despite strong performance from Keytruda. The company's proactive measures include ...
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than 12 months. Despite initial response to front-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results